medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-18-41-45medsovet-450Research ArticleКОГНИТИВНЫЕ НАРУШЕНИЯ И ДЕМЕНЦИЯCOGNITIVE IMPAIRMENT AND DEMENTIAБолезнь Альцгеймера: от теории к практикеAlzheimer's disease: from theory to practiceКотовА. С.KotovА. S.noemail@neicon.ruЕлисеевЮ. В.YeliseyevY. V.noemail@neicon.ruСеменоваЕ. И.SemenovaE. I.noemail@neicon.ruМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияMoscow Regional Research and Clinical Institute named after M.F. VladimirskiyRussian Federation2015301220150184145Copyright © Котов А.С., Елисеев Ю.В., Семенова Е.И., 20152015Котов А.С., Елисеев Ю.В., Семенова Е.И.Kotov А.S., Yeliseyev Y.V., Semenova E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/450

Болезнь Альцгеймера (БА) - самая частая причина деменции. Как правило, болезнь обнаруживается у людей старше 65 лет. В среднем пациенты с БА живут около 8-10 лет с момента появления первых клинических проявлений. Развитие БА связано с рядом факторов, которые делят на корригируемые (образ жизни) и некорригируемые (пол и возраст). В подавляющем большинстве случаев влияние генетических факторов на риск развития БА является низким. КТ, МРТ и лабораторные исследования помогают исключить другие возможные причины деменции. В настоящий момент не существует способов вылечить БА, но есть множество возможностей повысить качество жизни больного. Применение лекарственных средств может временно облегчить тяжесть некоторых симптомов или замедлить прогрессирование заболевания. Пациентам с умеренной или тяжелой стадией заболевания может быть назначен мемантин. Помимо медикаментозной терапии, эффективно когнитивное стимулирование. Наиболее целесообразной представляется комплексная терапия этого заболевания.

Alzheimer's disease (AD) is the most common cause of dementia. The disease is typically found in people over 65 years. On average, AD patients live for about 8-10 years after the onset of clinical manifestations. AD is conditioned by a number of factors which are subdivided into modifiable (lifestyle) and non-modifyable (sex and age). In most cases, the impact of genetic factors on the risk of developing AD is low. CT, MRI and laboratory tests help exclude other possible causes of dementia. At the moment, there is no cure from AD, though there are plenty of ways to improve the quality of life of patient. Use of drugs can temporarily relieve severity of certain symptoms or inhibit the progression of the disease. Memantine can be prescribed to patients with moderate to severe stage of the disease. In addition to drug therapy, cognitive stimulation is favourable. Multimodal therapy of the disease seems to be the most feasible way.

болезнь АльцгеймераАкатинолAlzheimer's diseaseAkatinolReferencesBermejo-Pareja F, Benito-Leon J, Vega S, et aL Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008 Jan. 15. 264(1-2): 63-72.Bermejo-Pareja F, Benito-Leon J, Vega S, et aL Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. J Neurol Sci. 2008 Jan. 15. 264(1-2): 63-72.Jelicic M, Bonebakker AE, Bonke B. Implicit memory performance of patients with Alzheimer's disease: a brief review. Int Psychogeriatr. 1995 Fall. 7(3): 385-92.Jelicic M, Bonebakker AE, Bonke B. Implicit memory performance of patients with Alzheimer's disease: a brief review. Int Psychogeriatr. 1995 Fall. 7(3): 385-92.Taler V, Phillips NA. Language performance in Alzheimer's disease and mild cognitive impairment: a comparative review. J Clin Exp Neuropsychol. 2008 Jul. 30(5): 501-56.Taler V, Phillips NA. Language performance in Alzheimer's disease and mild cognitive impairment: a comparative review. J Clin Exp Neuropsychol. 2008 Jul. 30(5): 501-56.Frank EM. Effect of Alzheimer's disease on communication function. J S C Med Assoc. 1994 Sep. 90(9): 417-23.Frank EM. Effect of Alzheimer's disease on communication function. J S C Med Assoc. 1994 Sep. 90(9): 417-23.Volicer L, Harper DG, Manning BC, et al. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry. 2001 May. 158(5): 704-11.Volicer L, Harper DG, Manning BC, et al. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry. 2001 May. 158(5): 704-11.Wilson RS, Barral S, Lee JH et al. Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study. J Alzheimers Dis. 2011. ;23(2): 249-55.Wilson RS, Barral S, Lee JH et al. Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study. J Alzheimers Dis. 2011. ;23(2): 249-55.Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006 Feb. 63(2): 168-74.Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006 Feb. 63(2): 168-74.Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006 Jul 29. 368(9533): 387-403.Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006 Jul 29. 368(9533): 387-403.Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012 Aug 2. 488(7409): 96-9.Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012 Aug 2. 488(7409): 96-9.Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1. 90(5): 1977-81.Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993 Mar 1. 90(5): 1977-81.Mahley RW, Weisgraber KH, Huang Y Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006 Apr 11. 103(15): 5644-51.Mahley RW, Weisgraber KH, Huang Y Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A. 2006 Apr 11. 103(15): 5644-51.Hall K, Murrell J, Ogunniyi A et al. Cholesterol, APOE genotype, and Alzheimer disease: an epi-demiologic study of Nigerian Yoruba. Neurology. 2006 Jan 24. 66(2): 223-7.Hall K, Murrell J, Ogunniyi A et al. Cholesterol, APOE genotype, and Alzheimer disease: an epi-demiologic study of Nigerian Yoruba. Neurology. 2006 Jan 24. 66(2): 223-7.Gureje O, Ogunniyi A, Baiyewu O, et al. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol. 2006 Jan. 59(1): 182-5.Gureje O, Ogunniyi A, Baiyewu O, et al. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol. 2006 Jan. 59(1): 182-5.Lambert JC, Ibrahim-Verbaas CA, Harold D et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013 Dec. 45(12): 1452-8.Lambert JC, Ibrahim-Verbaas CA, Harold D et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet. 2013 Dec. 45(12): 1452-8.Jonsson T, Stefansson H, Steinberg S et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013 Jan 10. 368(2): 107-16.Jonsson T, Stefansson H, Steinberg S et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 2013 Jan 10. 368(2): 107-16.Белова Ю.А. Смысл газетного заголовка: трудности интерпретации. Вестник Башкирского университета. 2013. 18. 3: 794-796.Белова Ю.А. Смысл газетного заголовка: трудности интерпретации. Вестник Башкирского университета. 2013. 18. 3: 794-796.Guerreiro R, Wojtas A, Bras J et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013 Jan 10. 368(2): 117-27.Guerreiro R, Wojtas A, Bras J et al. TREM2 variants in Alzheimer's disease. N Engl J Med. 2013 Jan 10. 368(2): 117-27.Francis PT, Palmer AM, Snape M et al. The cho-linergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb. 66(2): 137-47.Francis PT, Palmer AM, Snape M et al. The cho-linergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999 Feb. 66(2): 137-47.Shen ZX. Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease. Med Hypotheses. 2004. 63(2): 308-21.Shen ZX. Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease. Med Hypotheses. 2004. 63(2): 308-21.Wenk Gl. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry. 2003;64 Suppl 9:7-10.Wenk Gl. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry. 2003;64 Suppl 9:7-10.Mudher A1, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 2002 Jan. 25(1): 22-6.Mudher A1, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 2002 Jan. 25(1): 22-6.Polvikoski T1, Sulkava R, Haltia M et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995 Nov 9. 333(19): 1242-7.Polvikoski T1, Sulkava R, Haltia M et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med. 1995 Nov 9. 333(19): 1242-7.Holmes C1, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 Jul 19. 372(9634): 216-23.Holmes C1, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 Jul 19. 372(9634): 216-23.Казакова Е.К., Котов А.С. Когнитивные расстройства у пациентов с нарушением ритма сердца. Клиническая геронтология. 2013. 19. 11-12: 10-13.Казакова Е.К., Котов А.С. Когнитивные расстройства у пациентов с нарушением ритма сердца. Клиническая геронтология. 2013. 19. 11-12: 10-13.Ливиненко М.А., Котов А.С. Когнитивные нарушения у пожилых больных с цереброваскулярными заболеваниями. Клиническая геронтология. 2014. 20. 7-8: 9-11.Ливиненко М.А., Котов А.С. Когнитивные нарушения у пожилых больных с цереброваскулярными заболеваниями. Клиническая геронтология. 2014. 20. 7-8: 9-11.Богданов Р.Р., Борисова С.Ю., Котов С.В. Когнитивные и аффективные расстройства на ранних стадиях болезни Паркинсона. Альманах клинической медицины. 2015. 39: 90-96.Богданов Р.Р., Борисова С.Ю., Котов С.В. Когнитивные и аффективные расстройства на ранних стадиях болезни Паркинсона. Альманах клинической медицины. 2015. 39: 90-96.Сушкова М.О., Котов С.В., Якушина Т.И., и др. Нарушения когнитивных функций при рассеянном склерозе: ассоциация с активностью воспалительного процесса и степенью выраженности инвалидизации. Альманах клинической медицины. 2015. 39: 115-120.Сушкова М.О., Котов С.В., Якушина Т.И., и др. Нарушения когнитивных функций при рассеянном склерозе: ассоциация с активностью воспалительного процесса и степенью выраженности инвалидизации. Альманах клинической медицины. 2015. 39: 115-120.Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsycho-pharmacol Biol Psychiatry. 1986. 10(1): 87-93.Fleischhacker WW, Buchgeher A, Schubert H. Memantine in the treatment of senile dementia of the Alzheimer type. Prog Neuropsycho-pharmacol Biol Psychiatry. 1986. 10(1): 87-93.Reisberg B1, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3. 348(14): 1333-41.Reisberg B1, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3. 348(14): 1333-41.Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Jul 20. (3): CD003154.Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Jul 20. (3): CD003154.

The authors declare that there are no conflicts of interest present.